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Ob,jecdves . The purpose of this study was to determine whether
digoxin Is effective in patients with chronic, stable maid to mod-
crate heart failure .
dluckgrtn nd. lMgoxin has been a tradillonal therapy in heart
failure, but methodologie limitations in earlier studies have lire •
vented definitive conclusions regarding Its efficacy .
Methods . Withdrawal of digoxin (placebo group, n = 4(5) or its
continuation (digoxin group, u = 42) was performed in a prospec-
tive, randomised, double-blind,
placebo-controlled
mudticettter
trial of patients with chronic, stable mild to moderate heart failure
secondary to left ventricular systolic dysfunction who had normal
sinus rhythm and were receiving long-term treatment with di-
uretic drugs and digoxin.
Results . Patients withdrawn from digoxin therapy showed
worsened maximal exercise capacity (median change in exercise
Attempts to demonstrate the clinical efficacy of the digitalis
glycosides in patients with congestive heart failure and
normal sinus rhythm have progressed from presentations of
case series to prospectively designed clinical trials (1-8) . In
1982, Lee et al . (4) demonstrated for the first time in a
randomized placebo-controlled trial that, compared with
results achieved with placebo, digoxin resulted in improved
signs and lessened symptoms in patients with heart failure
who had normal sinus rhythm and were receiving mainte-
nance therapy with digoxin and diuretics . However, this
study was not totally convincing because 25% of patients
had an essentially normal heart failure score at baseline
.
There were also a high (29%) dropout rate, small sample
size, crossover design, hypertrophic cardiomyopathy in 8%
of patients and normal left ventricular systolic function in
24%. In 1988 Guyatt et al
. (5) demonstrated in a placebo-
controlled, randomized, double-blind study in patients with
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time -96 s) compared with that of patients who continued to
receive digoxin (change in exercise time +4.5 s) (p --- 0.003).
Patients withdrawn from digoxin therapy showed an increased
incidence of treatment failures (p = 0.039) (39%, digoxin with .
drawal group vs. 19%, digoxin maintenance group) and a de-
creased time to treatment failure (p = 0 .037) . In addition, patients
who continued to receive digoxin had a lower body weight (p =
0.044) and heart rate (p = 0.003) and a higher left ventricular
ejection fraction (p = 0.016).
Conclusions. These data provide strong' evidence of the clinical
efficacy of digoxin in patients with normal sinus rhythm and mild
to moderate chronic heart failure secondary to systolic dysfunc-
tion who are treated with diuretics .
(3' Am Coll Corn iol 1993;22:95$-62)
congestive heart failure and normal sinus rhythm an im-
provement with digoxin in submaximal (6-min walk) exer-
cise, a decrease in treatment failures and a reduction in
symptoms of dyspnea and heart failure score, as well as a
decrease in cardiothoracic ratio on chest X-ray film and
improvement in fractional shortening by echocardiography .
As in the study by Lee et al . (4), the trial used a crossover
design, and the sample size was quite small, limiting defini-
tive conclusions . In the same year, the German-Austrian
xamoterol study (6), a double-blind, placebo-controlled par-
allel group trial demonstrated that,
compared with placebo,
digoxin reduced symptoms and improved exercise capacity .
Although the sample size was large (n = 433) and all patients
had normal sinus rhythm, this study
was seriously flawed .
The extent of left ventricular systolic dysfunction in enrolled
patients was not defined, the etiology of heart failure was
unclear in 75% of the patients, only 23% were
taking diuretic
drugs, 25% were classified as having New York Heart
Association class I heart failure, and patients with angina
pectoris were enrolled . In addition,
the study used a 2 :1 :1
randomization (xamoterol : placebo
: digoxin), providing
greater power to demonstrate significant
effects with xamot-
erol than with digoxin
. Finally, only patients who completed
the trial were included in the analysis .
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In the same year, the Captopril-Digoxin Study (8), a large
(n = 300), double-blind, placebo-controlled, randomized
parallel group trial, demonstrated that patients with heart
failure taking digoxin with background therapy of diuretic
drugs required fewer hospitalizations and emergency room
visits than did patients receiving placebo with diuretic drugs .
In addition, compared with the placebo group, the digoxin
group showed fewer treatment failures, less need for addi-
tiivnal diuretics, and an increase in ejection fraction . This
study was biased against digoxin because most study pa .
tients had been receiving digoxin before the study and were
withdrawn from digoxin therapy before randomization. A
sizable percentage of patients were not entered into the
randomized phase because their condition deteriorated dur-
ing the withdrawal period ; thus, the patients who most likely
would have been responsive to digoxin were excluded from
the trial. In 1989, a large, double-blind, randomized placebo-
controlled parallel group trial, the miirinone-digoxin study
(two arms of which represented a randomized digoxin with-
drawal trial)
(7) demonstrated that continued treatment with
digoxin resulted in improved exercise capacity, reduced
need for co-intervention, reduced incidence of treatment
failures, a higher rate of study completion and improvement
in ejection fraction compared with results achieved with
placebo (that is, the digoxin withdrawal group).
Thus, recent data provide evidence that digoxin is, in
fact, clinically effective in patients who have chronic heart
failure and rormal sinus rhythm. Despite this evidence, the
use of digoxin in many parts of the world appears to be less
frequent than one might expect. For example, in a survey of
centers in the Studies of Left Ventricular Dysfunction
(SOLVD) trials, digoxin use ranged from almost 80% in
patients with four signs of congestive heart failure and a
left ventricular ejection fraction of <0 .20 to approximately
20% in patients with only one sign of congestive heart failure
and an ejection fraction of 0.36 to 0.45. Overall, ap-
proximately 5 0 of patients with left ventricular dysfunc-
tion with or without congestive heart failure from the
United States were taking digoxin compared with only
24% from Belgium and 41% from Canada . The three large
clinical trials cited earlier were primarily evaluating
another compound while utilizing digoxin as an active
control. Some of the design elements of these studies
enhanced evaluation of the primary drug in question rather
than of digoxin (for example, 2
:1:l randomization in the
xamoterol trial, digoxin withdrawal before randomization
in the Captopril-Digoxin Study) . The present study-the
Prospective Randomized
stud! of Ventricular Failure
and the Efficacy of Digoxin (PROVED)-was designed to
evaluate definitively and test specifically the efficacy and
safety of digoxin in patients with normal sinus rhythm who
had mild to moderate heart failure secondary to systolic
dysfunction and were receiving maintenance therapy with
digoxin and diuretics .
JACC Vol. 22. No . 4
October 1993 :955-62
Methods
This study was designed as a multicenter double-blind,
randomized, placebo-controlled and parallel group trial with
an 8-week single-blind baseline phase (physician but not
patient knowledge of the study drug, which in all cases was
digoxin) and a 12-week double-blind withdrawal phase .
Thirty-two centers participated, and all centers obtained
Institutional Review Board approval of the protocol and
informed, written patient consent . From I to II patients
(median 2) were recruited at each center, with 29 centers
entering <4 patients . The first patient was enrolled in June
1989 and the last in October 1990 . Recruitment of patients
became increasingly difficult soon after the study began, in
part because of the widespread use of angiotensin-
converting enzyme inhibitors . In July 1990, a decision was
made before unbinding by the study sponsor with the
consent of several principal investigators, including the
chairman of the study's advisory committee (B .F.U.), to halt
recruitment after 113 patients were enrolled in the single-
Wind phase and 88 patients were randomized in the double-
blind phase . The last follow-up visit occurred in April 1991 .
A companion trial (RADIANCE) (10) with identical meth-
odology except for the concomitant use of angiotensin-
converting enzyme inhibitors was conducted during the
same time period . By design, patients were limited to only
those currently taking digoxin and diuretic drugs for at least
I month before study entry. The use of an angiotensin-
converting enzyme inhibitor was an exclusion criterion .
Patient entry criteria . Entry criteria included patients
with mild to moderate chronic heart failure (functional class
11 or III) and normal sinus rhythm who were receiving
digoxin and diuretics . Each patient (? 18 years old) was
required to have a history of documented congestive heart
failure not caused by acute ischemia with evidence of
peripheral edema . jkguular venous distension, X-ray evidence
of interstitial edema or pulmonary congestion or a pulmo-
nary artery wedge pressure >12 mm Hg . An ejection frac-
tion determined by radionuclide angiogranhy to be s0 .35
and a left ventricular end-diastolic dimension X60 mm or
34 mmfm2 by echocardiography were required for entry .
Patients were excluded if they had had a myocardial
infarction within 3 months, unstable angina pectoris, a
cerebrovascular accident within 12 months, primary valvular
disease, hypertrophic cardiomyopathy, uncontrolled serious
ventricular arrhythmias, a history of atrial fibrillation, atrial
flutter or paroxysmal supraventricular tachycardia, hepatic
dysfunction as manifested by an elevation of serum glutamic
oxaloacetic transaminase or bilirubin twice normal or
greater, abnormal renal function (serum creatinine >2 .5 mg/di),
chronic obstructive pulmonary disease (forced expiratory
volume in 1 s/forced vital capacity <60% predicted),
exercise not limited by dyspnea or fatigue, hypertension
(diastolic blood pressure >95 mm Hg), hypotension (systolic
pressure <90 mm Hg), uncontrolled thyroid disease, myo-
carditis, amylotdosis, malignant disease or current use of
JACC Vol. 22, No. 4
October 1993:955-62
SINGLE BLIND
	
DOUBLE BLIND
BASELINE DIGOXIN WITHDRAWAL
STABILIZATION
N
Placetw- + Diuretic
W
IL Digoxin' t Diuretic ,
Digoxln' 4 Diuretic
I I I I I I I
VISIT NO.
1
2 3 4 5 6 7 8 9 10 11 12 13
STUDY WEEK 0 1 2 4 6 8 0 10 12 14 16 18 20
Hx X
PE  X X
NYHA X X x x X X X X X X X X
LWHF X x X X
GHF# X X X
ECHO
CXR X X X
MUGA
X X X
Err x x x x x x x
ECO X  x
LASS x x x x x
6 MIN WALK
x x X X X
(DIa1
X x x x
DIG A x x
GEP X X X X X A X X X X X X
• Dlgoxin Dose .0 .125, 0.25, 0 .3755
or 0.5 mg
00
t to 4 tatS OD
Figure 1 . The basic schema and major tests performed in the
PROVED trial . The text explains the procedure and methods
employed . CHF# = CHF score; CXR = chest X-lay film ; [DIG] =
serum digoxin concentration ; DIG 0 = investigator change of
digoxin dose, if required ; ECG = electrocardiogram ; ECHO =
M-mode echocardiography ; ETT = modified Naughton exercise
treadmill test ; GEP = 7-point Global Evaluation of Progress ; HX =
patient history; LABS = routine laboratory studies; MUGA =
radionuclide angiography ; NYHA = New York Heart Association
functional class ; PE = physical examination; LWHF = Living with
Heart Failure questionnaire ; 6 MIN WALK = 6-min walking test ;
QD = once daily .
concomitant medications including tricyclic antidepres-
sants, phenothiazines, vasodilators including angiotensin-
converting enzyme inhibitors and nitrates, beta-adrenergic
blocking agents, calcium channel blocking agents and anti-
arrhythmic drugs with negative inotropic properties .
Study design. The primary end points of the study were
1) treadmill time on maximal exercise testing, 2) distance
covered during a 6-min walking test (11), 3) incidence of
treatment failure, and 4) time to treatment failure . Secondary
end points included change in signs and symptoms of con-
gestive heart failure, quality of life using the Minnesota
Living with Heart Failure questionnaire (12), congestive
heart failure score (4), 7-point Global Evaluation of
Progress, left ventricular ejection fraction by radionuclide
.ingiography, left ventricular dimensions by echocardiogra-
phy, vital signs and body weight . Also, routine biochemical
variables, electrocardiogram (ECG) and serum digoxin con-
centration were monitored as safety indexes .
To ensure clinical stability before randomization, an
8-week single-blind stabilization period was mandated (Fig .
1). During this period, serum digoxin concentration was
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obtained at three time points, and dose adjustments were
made to ensure a serum digoxin concentration between 0 .9
and 2.0 ng/ml for at least 2 weeks before double-blind
randomization . At the time of double-blind randomization,
the prescribed digoxin dose required to attain the specified
serum digoxin concentration during the single-blind period
(or a corresponding placebo dose) was provided during the
double-blind period . Patients assigned to placebo therapy
were therefore withdrawn from treatment with digoxin . In
addition, a fixed diuretic regimen was required for at least 4
weeks before double-blind randomization . Exercise criteria
for entering the double-blind study phase included walking
between 2 and 12 min on the first of at least four modified
Naughton treadmill tests and between 2 and 14 min at the
final test, with a <60-s difference between the results of the
last two exercise tests . The results of the last single-blind
treadmill test were considered as the "baseline value" for
comparison with subsequent tests. Patients were exercised
to maximal effort, with a Burg score of ?19 (13).
Patients were seen at weeks 1, 2, 4, 6 and 8 during the
single-blind stabilization phase . During the double-blind
phase, patients were scen every 2 weeks for 3 months . At
each visit, vital signs, brief physical examination, 7-point
Global Evaluation of Progress, signs and symptoms of heart
failure and functional class were determined . At study weeks
1, 4, 6 and 8 of the single-blind and weeks 10, 14 and 20 (2,
6 and 12 weeks of the double-blind period), exercise tread-
mill tests were performed (see flow diagram, Fig . I, for a
schedule of all tests). The 6-min walking test for total
distance was performed at weeks 2 and 8 of the single-blind
period and at study weeks 12, 16 and 18 (4, 8 and 10 weeks
of dottble-blind therapy) . The Living with Heart Failure
questionnaire was administered at 4 and 8 -weeks in the
single-blind phase and at 12 and 20 weeks during the double-
blind period. Congestive heart failure score, echocardio-
gram, 'best X-ray film and radionuclide angiograms were
obtained before study and at weeks 8 and 20 . Laboratory
studies were obtained at 2, 8, 12 and 20 weeks . During the
double-blind period, study staff members made semiweekly
telephone calls to patients to assess the signs and symptoms
of heart failure .
During the double-blind period, an increase in diuretic
therapy, addition of new medications for heart failure and
dr ath or admission to an emergency room or hospital for
heart failure were defined as a treatment failure . Death was
not a primary end point because this was not a mortality
trial .
After termination of recruitment and follow-up (and be-
fore unblinding), a subcommittee of investigators reviewed
each reported treatment failure and admission to the hospital
or emergency room to ascertain if the event was secondary
to congestive heart failure
. Each death was oho revi-wed in
a blinded fashion to assess its cause
. A consensus was
reached with each case ; cases deemed not related to heart
failure were considered wit :drawn to follow-up at that point
but not a treatment failure .
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The Ethics Committee reviewed and approved the final
protocol and was charged to review
adverse events and
deaths by a priori rule after each 100 randomized patients .
Because the study was terminated after 88 patients were
randomized, the committee did not convene for this latter
PUMM-
Stadmieal mehodti
. An intention-to-treat analysis based
on groupp assignment was used for all primary end points .
The number of patients to be recruited was estimated by the
expectation of differences in exercise treadmill time. Assum-
ing a difference in exercise time between digoxin and pla-
ccbo groups of 50 s and an SD of 150 s, it was originally
estimated that 300 patients would be required to make a
conclusion with 90% power (alpha = 0 .05, one-tailed) . A
; onpahametric approach was used to analyze changes in
treadmill exercise duration and 6-min walk distance . Treat-
ment group comparisons were made using the extended
Mantel-Haenszel statistic (Cochran-Mantel-Haenszel) strat-
ified by center and adjusted for two covariates, baseline
exercise time/distance and ejection fraction (14) . Patients
who died or were withdrawn from the double-blind phase as
treatment failures with no final exercise tests had a final
exercise duration of lowest rank assigned and carried for-
ward to the remaining time points. Other patients who
prematurely discontinued the study had their final double-
blind exercise duration carried forward, Carry-forward anal-
yses were also used for the 6-min walk, signs and symptoms
of congestive heart failure, physical examination, patient's
Global Evaluation of Progress, congestive heart failure score
and quality of life. For the analysis of New York Heart
Association functional class and patient's Global Evaluation
of Progress, patients who died or were classified as treat-
mutt failures with missing values on the date of treatment
failure were assigned the wont score (that is, functional
class IY and "much worse" on the Global Evaluation of
Progress). For the analysis of signs and symptoms of con-
gestive heart failure, the worst score was not assigned
because it could not be assumed that all signs and symptoms
were most severe at the time of treatment failure or death ;
therefore, the final double-blind score was carried forward .
For continuous variables such as left ventricular ejection
fraction and echocardiographic variables, an analysis of
covariance, using the baseline as the covariate, was per
formed .
The proportion of patients characterized as treatment
failures and the incidence of adverse effects were compared
using a Pearson chi-square test (15) and, where there were
few events, the Fisher exact test. The distribution of time to
treatment failure were compared between groups using the
log-rank test (16) . The distribution of clinical signs and
symptoms and other categoric data were compared using the
mean rank score version of the Cochran-Mantel-Haenszel
statistic adjusted for investigator . To test the comparability
of treatmr-at gm.ps at baseline, an analysis of variance for
continuous :ariables (17) and a Cochran-Mantel-Haenszel
test for categoric data were utilized(18). Both analyses were
Table 1. Baseline Demographic and Ventricular Function
Variables of Patients Randomized to Placebo and
Digoxin Treatment
JACC Vol . 22. No. 4
October 1993 :955-62
Continuous variables are presented as mean value t SEM. CHF
congestive heart failure ; 1CM
-
ischetaic cardiomyopathy : LVEDD
a
left
ventricular end-diastolic dimension ; LVEF
-
left ventricular ejection frac-
tion : NYHA New York Heart Association functional classification .
adjusted for investigator differences. Although sample size
estimates were initially based on a one-sided hypothesis, the
results of this study were tested and reported herein, using a
two-sided hypothesis, with alpha = 0.05. Baseline was
defined as the last value obtained before administration of
the double-blind study drug.
Study patients. A total of 113 patients were entered into
the single-blind phase, and 88 patients were subsequently
entered into the double-blind phase . Of these, 46 patients
were randomized to placebo and 42 to digoxin therapy . Of
the 25 patients who withdrew during the single-blind phase,
15 patients (60%) had either an adverse event or an intercur-
rent event unrelated to digoxin use, 4 patients (16%) had a
protocol violation, and 2 patients each (8%) were either
admitted to the hospital for worsening congestive heart
failure, did not meet entry requirements for the double-blind
period or withdrew consent. Adverse intercurrent events
during the single-blind period included two deaths (one
sudden and one occurring after an acute myocardial infarc-
tion), one cardiac arrest in a patient who was resuscitated,
six noncardiac events and six cardiac events not directly
related to heart failure (development of atrial fibrillation in
three patients who had normal sinus rhythm and worsening
angina pectoris, second degree atrioventricular block or
ventricular tachycardia in one patient each).
The demographic data and ventricular function were
similar in the two groups (Table 1) . Signs and symptoms of
congestive heart failure were similar except a larger percent-
age (p = 0 .02) of the group randomized to continued digoxin
therapy than of the placebr: group had jugular venous
distension (45% vs. 22%). In addition, the Living with Heart
Failure Questionnaire showed, at baseline, more physical
impairment (p = 0.04) in the digoxin group than in the
placebo group, based on a score of ?100 (67% vs . 51%) .
Placebo
Group
(n = 46)
Digoxin
Group
(n = 42)
Age (yr) 64±2 64±2
Men/women 37/9 3814
NYHA class lI or III 38/7 3517
LVEF (%) 29±2 271 I
Cardiothoracic ratio 0.5 ± 0.01 0.5 t 0.01
LVGDD (mm) 67 ± 1 67 ± I
Duration of CIF (yr) 3 .1 = 0.5 3.6 * 0 .5
Etiology of CHF 1%) (ICM/
non-ICM)
67/33 60140
Serum digoxin level (nglml) I .! :.± 0.05 1 .2 10.05
Median digoxin dose (mg) 0 .375 0.375
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Figure 2. The change (in seconds) in maximal exercise time of
patients continued on digoxin treatment compared to patients re-
ceiving placebo . The difference in this change between the two
groups was highly significant . The number of study weeks repre-
sents the time from double-blind randomization.
Results
Three of the four primary end points demonstrated sig-
nificant differences between the two groups . Median exer-
cise duration at baseline was 540 s in the placebo group and
494 s in the digoxin group . Patients receiving placebo dem-
onstrated significant (p = 0 .003) worsening of maximal
exercise performance compared with that of patients receiv-
ing digoxin (Fig . 2) . There was a median decrease of 96 s at
12 weeks in the placebo group and a 4 .5-s increase in the
digoxin group. Patients randomized to placebo demonstrated
a higher percentage of treatment failures (39% vs . 19%, p =
0.039) and a decreased time to treatment failures (p = 0 .037)
(Fig. 3, Tables 2 and 3) compared with patients maintained
on digoxin . Of the primary end points, only the submaximal
exercise test (6-min walk) did not demonstrate a statistically
significant effect of digoxin .
Of the secondary end points, left ventricular ejection
fraction at the end of the double-blind period was signifi-
cantly higher (p = 0 .016) in the digoxin than in the placebo
group (Table 4), whereas heart rate (p = 0.003) and body
weight (p = 0.044) were lower in the digoxin- than in the
placebo-treated group.
There were no significant differences between the two
groups at the end of the double-blind period in changes in
most signs and symptoms of heart failure, congestive heart
failure score or the Living with Heart Failure questionnaire .
However, at entry into the double-blind phase, <50% of the
patients had an abnormality in most variables (for example,
orthopnea and jugular venous distension) or only mild symp-
toms, such as dyspnea, at baseline . Thus, the ability to
demonstrate improvement in these variables in the patient
group was limited . However, there was clearly a trend to
worsening in most variables in the placebo group as com-
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Figure 3. The number of patients and cumulative incidence (l%) of
treatment failures (A) and time to treatment of heart failure (B)
during the double-blind period . A highly significant increase in rate
and cumulative incidence of treatment failures is observed in the
placebo group compared with results in the digoxin group .
pared with the digoxin group (Fig. 4) . Because a sig aificantly
higher percentage of patients in the placebo than in the
digoxin group withdrew as treatment failures and because
many of the secondary end points were not assessed at the
time of treatment failure, it is likely that the differences
would have been magnified had actual pretreatment failure
values been included rather than "carry forward" values
obtained at more remote times before study withdrawal .
There was a trend toward an increase in left ventricular
end-diastolic dimension in the placebo group (1 .3 ± 1
.6 mm)
as compared with the digoxin group (0.4 ± 1 .5 mm). The
difference at the end of the double-blind period in blood urea
nitrogen and serum creatinine was significant (Table 4) .
The overall percentage of patients with one or more
ad-- •erse experiences of any type during the double-blind
period was similar in the two groups : 59% (27 of 46) in the
placebo group and 69% (29 of 42) in the digoxin group .
There were no clinical episodes of digitalis toxicity. By
intention-to-treat analysis, there were two deaths in the
placebo group and one in the digoxin group during the
double-blind period .
One blinded treatment failure review committee determined that one
additional patient in the placebo group had worsened heart failure requiring an
increase in drug therapy on the last study visit (Table 3) . This patient is not
included in Table 2 because the patient was not withdrawn prematurely from
the trial, The committee also determined that one of the five patients in the
digoxin group withdrawn because of Increased drug therapy did not, in fact,
have worsened heart failure (Table 3). These patients include one patient
each in the placebo group with a protocol violation, loss to follow-up, and
withdrawal of consent and on patient in the digoxin group with withdrawal of
consent .
Discussion
The results of this study provide strong evidence that
digoxin is effective in treating patients with chronic conges-
tive heart failure secondary to systolic dysfunction %iho have
mild to moderate symptoms and normal sinus rhythm .
Specifically, withdrawal of digoxin resulted in a significant
worsening of exercise performance and an increased inci-
dence of, and a decreased time to, treatment failure . Addi-
tiomtl evidence of clinical efficacy was an increase in ejection
fraction and a decrease in body weight and heart rate in the
digoxin group.
The conclusions of this study are strengthened by the
rigor employed to establish a stable baseline . The length of
the
single-blind
baseline phase (8 weeks), the requirement of
a minimum of four baseline exercise tests, the last two within
50 s of each other, and an insistence on unchanged medical
therapy for 4 weeks before double-blind entry represent
extremely stringent criteria for baseline stability . That such
tncressed drug therapy
Hospital admiss(al for
worsmed heart hildre
Ersavency,
roan treatment for
worsened beaus failure
Death
Total
'Ibis patient later also died but is not included under Death
.
Figure 4. The relative clinical benefit of digoxin at 12 weeks of the
double-blind phase was calculated by measuring relative improve-
ment of the digoxin group over that of the placebo group and
subtracting the relative worsening . (Relative benefit = relative
improvement minus relative worsening.) Relative improvement
(worsening) for each variable was calculated as percent of digoxin-
treated patients with improvement (worsening) minus the percent of
placebo-treated patients with improvement (worsening) . For exam-
ple, in the dyspnea category improvement occurred in 24% of the
digoxin group and in 11% of the placebo group . Thus, the rela-
tive digoxin improvement was 13%. Worsening occurred in 19% of
the digoxin group and in 29% of the placebo group. Thus, relative
worsening for digoxin was -10% (19% to 29%) . Therefore, the
relative benefit of digoxin in the dyspnea category was 13% (relative
improvement) -- (- 100) (relative worsening) = +23%. The percent
of patients classified as showing "no change" is not included in
either group. HF
:
heart failure; J VD = jugular venous distension ;
other abbreviations as in Figure I .
baseline stability was, in fact. achieved is perhaps best
demonstrated by the virtually unchanged maximal exercise
capacity observed after randomization in patients who con-
tinued digoxin treatment (Fig . 2). In addition, strict attention
to adequate digitalization was ensured before digoxin with-
drawal during the double-blind phase .
A limitation of this study is the relatively small number of
patients included. The nearly universal use of angiotensin-
converting enzyme inhibitors made timely patient recruit-
ment impossible . Nevertheless, the study was able to demon-
strate efficacy in three of the four primary end points . In the
companion trial, RADIANCE, which required angiotensin-
converting enzyme inhibitors as background therapy and
recruited approximately twice the number of patients in-
cluded in the present PROVED study, all four primary end
points showed significant treatment differences in favor of
digoxin (10) . In the subjective and difficult to quantify
measures of signs and symptoms of heart failure, there was
an internal consistency in this study with a trend toward
worsening of signs and symptoms in the placebo group and a
trend toward improvement in the digoxin group (Fig . 4). This
trend u as present even though actual values for these
secondary end points were usually not obtained before
patient withdrawal because of treatment failure and values at
the point of pretreatment failure (which were likely to be less
Table 3. Treatment Failures
Placebo
Digoxin
Group Group
(n - 46)
(a-42)
Causes of Treatment Failure
(no
. l%l)
(no. (%]) p Value
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Table 2
. Reasons for Withdrawal From the Trial
RELATIVE BENEFIT (%)
PLACEBO DIGOXIN
Placebo
Digoxin 20 io a 10
E0 30 40
Group
Group
DYSPNEA
(n = 46) (n = 42)
FATIGUE
Reasons for Withdrawal (no . [%I)
(no.
(%))
p Value
NTNA CLASS
Increase in drug therapy for
9 [201 51121
ORTHOPHEA
worsening heart failure*
RALES
Hospital, admission for worsening 6[131 3171
PERIPHERAL EDEMA
beset failure
JYD
Emergency room treatment fbr
1121 0101
worsening heart failure
THIRD HEART SOUND
Intereurrontfadvene events 2(41
1121
HEPATOMEDALY
P~II
(includes death)
OLCOAL EVALUATION
Oth"+ 3161 1121
,IF SCORE
Total 211461 101241 0.032
LWHF SCORE
10(221
4(101
6[131 317(
1121* 0 [01
1(21 1[21
18 [391
81191 0 .039
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Table 4. Significant Differences in Secondary End Points and Safety Variables Between Digoxin and Placebo Groups at the End of the
Double-Blind Period
severely abnormal) were carried forward. Because most
symptoms and signs of heart failure were absent or minimal
in at least 50% of the patient group, it is possible that a much
larger cohort than that in the PROVED trial would have been
necessary to document differences in all these variables .
A frequent clinical situation is that of a patient who had
an episode of congestive heart failure sometime in the past,
has been clinically stable for a prolonged period on mainte-
nance digoxin therapy and whose physician is considering
whether digoxin therapy can be discontinued. The present
data argue that a patient who continues to have even mild
functional limitation and has both a reduced ejection fraction
and left ventricular dilation, is at risk of clinical deterioration
if digoxin therapy is withdrawn .
An extremely important issue is whether the results of the
present withdrawal study can be applied to congestive heart
failure patients for initiation of digoxin therapy . Although it
may be considered a leap of faith to do so, we consider the
extrapolation small, given the rigor of the study design, the
strength of the positive results and the fact that the patients
in the present study were originally treated with digoxin by
their treating physicians to improve their clinical state and
functional capacity .
One question raised by the results of this study is whether
one needs to titrate to a serum digoxin concentration for
clinical efficacy . In the present study, the purpose of titrating
digoxin dose to serum concentration was to ensure that
serum digoxin concentrations would be within the generally
accepted therapeutic (0 .9 to 2 .0 nglmi) and not toxic range .
In fact, the mean digoxin concentration achieved in this
study was in the middle of this range (1 .2 nglml). Further-
more, the serum concentrations at the various doses before
double-blind randomization were not different . The lack of
digitalis toxicity suggests that this approach was effective .
A secondary reason for utilizing serum digoxin concen-
trations was to ascertain that a reasonable concentration
(>0.8 ng/ml) was present to test the efficacy of digoxin most
effectively. These precautions to assure safety do not imply
that the clinician must titrate to a certain serum digoxin
concentration. This study did not test the relative efficacy of
digoxin at different doses or at different seruia concentra-
tions to validate this approach to therapy .
The median (0.375 mg) dose of digoxin in this study may
be viewed as high compared with doses most often used in
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present clinical practice. This study was confined to patients
with chronic heart failure, relatively normal renal function
and without extremely poor systemic flow, as judged by the
patient's clinical state . In patients with these problems or
with acute heart failure, lower doses may be adequate to
produce comparable serum concentrations .
It might be argued that these data are no longer clinically
relevant because currently accepted medical therapy for
chronic congestive heart failure secondary to systolic dys-
function and normal sinus rhythm includes angiotensin-
converting enzyme inhibitors. The purpose of this study was
to evaluate the clinical efficacy of digoxin rather than con-
sider its efficacy as part of a therapeutic strategy including
background angiotensin-converting enzyme inhibition . The
latter evaluation was performed in the RADIANCE trial
(10) . Both studies demonstrated the clinical efficacy of
digoxin with or without background angiotensin-converting
enzyme inhibition .
The effect of digoxin on survival was not addressed in this
study and remains an important issue to be resolved . A study
sponsored by the National Heart, Lung, and Blood Institute
ant+ the Veterans Affairs Cooperative Studies Cenier, which
plans to enroll 8,000 patients (DIG), is underway in North
America to test the effect of digoxin on survival and major
morbidity. Because a difference between favorable clinical
effects and an adverse effect on survival has been observed
with certain other agents used it ; congestive heart failure
(7,19), it seems reasonable to proceed with this study despite
the positive results of the PROVED and RADIANCE trials .
We express our sincere appreciation to Mrs . Rhonda Oliver for preparation
of
this manuscript .
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Creat (mg1100 ml) 1 .2 ± 0.05 1 .2 ± 0 .05 0.09 ± 0.04 -0.02 t 0.04 0.024
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